


**VYVGART® Hytrulo**  
(efgartigimod alfa and hyaluronidase-qvfc)  
Subcutaneous Injection  
180 mg/mL and 2000 U/mL vial

**VYVGART®**  
(efgartigimod alfa-fcab)  
Injection for Intravenous Use  
400 mg/20 mL vial



# GENERALIZED MYASTHENIA GRAVIS doesn't get to capture this moment

## **What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?**

VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

### **SELECT IMPORTANT SAFETY INFORMATION**

VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections.

**Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART for IV infusion and VYVGART HYTRULO for subcutaneous injection.**



## About VYVGART ..... 3

How it's given and how it works in the body



## Study data ..... 5

Learn about the 2 VYVGART studies



## Safety ..... 9

Learn about safety and side effects



## Getting started ..... 11

Helpful things to know and talk to your doctor about



## Dosing ..... 13

Learn about treatment plans and personalized breaks



## My VYVGART Path ..... 15

Support and resources for every step of your journey



## Important Safety Information ..... 17

# VYVGART Hytrulo could mean more time for you

**VYVGART Hytrulo offers a ~30 to 90-second subcutaneous injection**

**VYVGART Hytrulo can be given at an:**



**infusion center,**



**doctor's office,**



**or at home\***

VYVGART for intravenous (IV) infusion is also available, and is given over 1 hour at an infusion center, doctor's office, or at home.\*

For at least 30 minutes after your subcutaneous injection or 1 hour after your IV infusion, a healthcare professional will monitor you for allergic reactions.



➔ Learn about VYVGART Hytrulo for subcutaneous injection at [StartVYVGART.com](https://StartVYVGART.com)

VYVGART Hytrulo has 2 active ingredients: efgartigimod alfa, which is the same active ingredient in VYVGART for IV infusion, and hyaluronidase (human recombinant). Hyaluronidase helps to increase the distribution and absorption of ingredients into the body.

\*In some cases, VYVGART Hytrulo for subcutaneous injection or VYVGART for IV infusion may also be given at home by a trained nurse.  
IV=intravenous

## SELECT IMPORTANT SAFETY INFORMATION

Before taking VYVGART or VYVGART HYTRULO, tell your doctor if you: take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines; have received or are scheduled to receive a vaccine (immunization); or have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

**Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART for IV infusion and VYVGART HYTRULO for subcutaneous injection.**

# How VYVGART works in the body

**VYVGART helps reduce harmful AChR antibodies, the main cause of gMG symptoms**

**VYVGART is specifically designed to cause a reduction in the number of IgG antibodies, including harmful AChR antibodies**



## FcRn receptors

When attached, receptors called neonatal Fc receptors (FcRn) extend the life of IgG antibodies, including harmful AChR antibodies. Those that don't attach to FcRn receptors are removed by the body.

+



## VYVGART

VYVGART is designed to have an attraction to FcRn receptors.

=



## FcRn receptors + VYVGART

VYVGART attaches to FcRn receptors so they can't attach to harmful AChR antibodies.

**This results in some harmful AChR antibodies being removed by the body.**

➔ See the science behind these targeted treatments at [VYVGARTMOA.com](https://www.vyvgartmoa.com)

AChR=acetylcholine receptor; FcRn=neonatal Fc receptor; gMG=generalized myasthenia gravis

## SELECT IMPORTANT SAFETY INFORMATION

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives. These are not all the possible side effects of VYVGART and VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

**Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART for IV infusion and VYVGART HYTRULO for subcutaneous injection.**



## 2 studies looked at effectiveness and safety

Patients in both studies were adults (18 years or older) with anti-AChR antibody positive gMG and were taking a stable dose of their current oral gMG treatment throughout the study. Results in the studies were measured after 1 treatment cycle.



### The VYVGART study

#### Study design

167 patients received either VYVGART for IV infusion or a placebo plus their current oral gMG treatment

#### The main goals:

- Study the safety of VYVGART for IV infusion
- Study its effectiveness in 2 areas:
  - Daily abilities as measured by the MG-ADL scale
  - Muscle weakness as measured by the QMG scale



### The VYVGART Hytrulo study

#### Study design

110 patients received either VYVGART for IV infusion or VYVGART Hytrulo for subcutaneous injection plus their current oral gMG treatment

#### The main goals:

- Compare the safety of both treatments
- Compare antibody reduction with both treatments

AChR=acetylcholine receptor; gMG=generalized myasthenia gravis; IV=intravenous; MG-ADL=Myasthenia Gravis Activities of Daily Living; QMG=Quantitative Myasthenia Gravis

### SELECT IMPORTANT SAFETY INFORMATION

VYVGART and VYVGART HYTRULO may cause serious side effects, including infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART for IV infusion and VYVGART HYTRULO for subcutaneous injection.

## STUDY DATA

**VYVGART® Hytrulo**  
(efgartigimod alfa and hyaluronidase-qvfc)  
Subcutaneous Injection  
180 mg/mL and 2000 U/mL vial

**VYVGART®**  
(efgartigimod alfa-fcab)  
Injection for Intravenous Use  
400 mg/20 mL vial

### THE VYVGART FOR IV INFUSION STUDY

# Proven to improve daily abilities and reduce muscle weakness



## IMPROVED DAILY ABILITIES

### More than 2x as many patients saw improved daily abilities

**68% (44 of 65)** of patients who added VYVGART for IV infusion to their current oral gMG treatment significantly improved their ability to perform daily activities during their first treatment cycle, as measured by the MG-ADL scale.\* Compared to **30% (19 of 64)** of patients on placebo plus their current oral gMG treatment.



## REDUCED MUSCLE WEAKNESS

### More than 4x as many patients saw reduced muscle weakness

**63% (41 of 65)** of patients who added VYVGART for IV infusion to their current oral gMG treatment saw a significant reduction in muscle weakness during the first treatment cycle, as measured by the QMG scale.† Compared to **14% (9 of 64)** of patients on placebo plus their current oral gMG treatment.

\*"Improved daily abilities" was defined as a decrease of 2 or more points on the MG-ADL scale. The improvement had to be maintained for 4 or more weeks, with the first improvement occurring within 1 week of the last infusion of treatment cycle 1. The MG-ADL scale measures the severity of 8 common symptoms of gMG. A lower score means less severe symptoms.

†"Reduced muscle weakness" was defined as a decrease of 3 or more points on the QMG scale. The improvement had to be maintained for 4 or more weeks, with the first improvement occurring within 1 week of the last infusion of treatment cycle 1.

The QMG scale assesses muscle weakness in gMG based on 13 items. A lower score means less muscle weakness.

gMG=generalized myasthenia gravis; IV=intravenous; MG-ADL=Myasthenia Gravis Activities of Daily Living;

QMG=Quantitative Myasthenia Gravis

## SELECT IMPORTANT SAFETY INFORMATION

VYVGART and VYVGART HYTRULO may cause serious side effects, including infection. VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.

**Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART for IV infusion and VYVGART HYTRULO for subcutaneous injection.**

## STUDY DATA

**VYVGART® Hytrulo**  
(efgartigimod alfa and hyaluronidase-qvfc)  
Subcutaneous Injection  
180 mg/mL and 2000 U/mL vial

**VYVGART®**  
(efgartigimod alfa-fcab)  
Injection for Intravenous Use  
400 mg/20 mL vial

### THE VYVGART HYTRULO STUDY

# Different delivery, similar effect

VYVGART Hytrulo for subcutaneous injection and VYVGART for IV infusion had a similar average reduction in the harmful AChR antibodies that cause gMG symptoms.



#### **VYVGART Hytrulo**

reduced harmful  
AChR antibodies by

**62%**



#### **VYVGART**

reduced harmful  
AChR antibodies by

**60%**

**In the VYVGART for IV infusion study,** a reduction in harmful AChR antibodies was associated with improved daily abilities when added to patients' current oral gMG treatment.

AChR=acetylcholine receptor; gMG=generalized myasthenia gravis;  
IV=intravenous



## SELECT IMPORTANT SAFETY INFORMATION

VYVGART and VYVGART HYTRULO may cause serious side effects, including allergic reactions (hypersensitivity reactions). VYVGART and VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.

**Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART for IV infusion and VYVGART HYTRULO for subcutaneous injection.**

## STUDY DATA

**VYVGART® Hytrulo**  
(efgartigimod alfa and hyaluronidase-qvfc)  
Subcutaneous Injection  
180 mg/mL and 2000 U/mL vial


**VYVGART®**  
(efgartigimod alfa-fcab)  
Injection for Intravenous Use  
400 mg/20 mL vial

### THE VYVGART FOR IV INFUSION STUDY

## Additional data

The following data point was not the main goal of the study and does not carry the same weight as the main goals of the study. **No reliable conclusions can be drawn about the effectiveness or safety of VYVGART for IV infusion based on this data point.** Talk to your neurologist if you have any questions.

### MG-ADL data during treatment cycle 1



gMG=generalized myasthenia gravis; IV=intravenous; MG-ADL=Myasthenia Gravis Activities of Daily Living

➔ Learn more about the study data for VYVGART Hytrulo for subcutaneous injection and VYVGART for IV infusion at [VYVGARTResults.com](https://www.vyvgartresults.com)


### SELECT IMPORTANT SAFETY INFORMATION

VYVGART and VYVGART HYTRULO may cause serious side effects, including infection. VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.

**Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART for IV infusion and VYVGART HYTRULO for subcutaneous injection.**



## VYVGART for IV infusion has a demonstrated safety profile



In the VYVGART for IV infusion study, these side effects were reported in **at least 5% of patients on VYVGART** plus their current oral gMG treatment, and more frequently than in patients on placebo plus their current oral gMG treatment.

- Most infections in patients on VYVGART plus their current oral gMG treatment were mild to moderate
- Additionally, more patients on VYVGART compared to placebo plus current oral gMG treatment had lower white blood cell counts that were mild to moderate in severity

gMG=generalized myasthenia gravis; IV=intravenous

### Information about allergic and infusion-related reactions

VYVGART for IV infusion can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. It can also increase the risk of serious allergic reactions such as trouble breathing and decrease in blood pressure leading to fainting, as well as infusion-related reactions including increase in blood pressure, chills, shivering, and chest, abdominal, and back pain. These reactions can occur during or after treatment and can cause doctors to pause or, in some cases, stop treatment.

Please see Important Safety Information throughout. Please see the full Prescribing Information for **VYVGART for IV infusion** and **VYVGART HYTRULO for subcutaneous injection**.

# VYVGART Hytrulo has a similar safety profile



The overall safety of VYVGART Hytrulo for subcutaneous injection was consistent with the safety profile of VYVGART for IV infusion, except patients on VYVGART Hytrulo experienced more injection site reactions.

## The safety of VYVGART Hytrulo was established through 2 studies

**In the VYVGART for IV infusion study**, the most common side effects of VYVGART for IV infusion-treated patients were respiratory tract infection, headache, and urinary tract infection. More patients had lower white blood cell counts that were mild to moderate in severity vs placebo.

**In the VYVGART Hytrulo study**, the most common side effects of VYVGART Hytrulo-treated patients were injection site reactions, 38% (21 of 55), and headache. Injection site reactions included injection site rash, redness of the skin, itching sensation, bruising, pain, and hives.

## In the VYVGART Hytrulo study and its long-term safety study:

- All injection site reactions were **mild to moderate** and didn't lead to treatment discontinuation
- The majority of injection site reactions **occurred within 24 hours** of injection and resolved on their own
- The majority of injection site reactions **occurred during the first treatment cycle** and decreased with each subsequent cycle

IV=intravenous

## Information about allergic and infusion-related reactions

VYVGART Hytrulo can cause allergic reactions such as rashes, swelling under the skin, shortness of breath, and hives. It can also increase the risk of serious allergic reactions such as trouble breathing and decrease in blood pressure leading to fainting, as well as infusion-related reactions including increase in blood pressure, chills, shivering, and chest, abdominal, and back pain. These reactions can occur during or after treatment and can cause doctors to pause or, in some cases, stop treatment.

**Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART for IV infusion and VYVGART HYTRULO for subcutaneous injection.**

# Things to discuss with your doctor before starting VYVGART



## No specific vaccines required to start treatment

Talk to your doctor about age-appropriate vaccines before you start treatment.



## No routine lab monitoring required

Routine lab monitoring isn't required, but your doctor will still monitor your response to treatment and look out for possible side effects.



## Your MG-ADL score

Find out what your current score is and talk to your doctor about how to track it consistently.



## Safety

Ask your doctor about the side effects you may experience on VYVGART.



## Treatment location

Talk through your needs, preferences, coverage, and other factors to understand your options.

MG-ADL=Myasthenia Gravis Activities of Daily Living



Learn about cost and coverage for VYVGART Hytrulo for subcutaneous injection and VYVGART for IV infusion at [VYVGARTaccess.com](https://www.vyvgartaccess.com)

## SELECT IMPORTANT SAFETY INFORMATION

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART or VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Please see Important Safety Information throughout. Please see the full Prescribing Information for [VYVGART for IV infusion](#) and [VYVGART HYTRULO for subcutaneous injection](#).

# VYVGART for IV infusion is the #1 prescribed FDA-approved biologic treatment for adults with anti-AChR antibody positive gMG\*

VYVGART for IV infusion has been FDA approved for more than 3 years.

## VYVGART is widely available

**90%** of commercial and Medicare insured patients have coverage for VYVGART or VYVGART Hytrulo†

## Multiple treatment cycles are possible with the first prescription

**90%** of commercial and Medicare insured patients have coverage allowing for an initial authorization of VYVGART or VYVGART Hytrulo for at least 6 months.† This can allow for multiple infusion cycles with the first prescription

\*Based on IQVIA LAAD data from January 2023 to April 2024. Data is based on validated claims of VYVGART for IV infusion and other biologics that have been approved by the FDA for the treatment of adults with anti-AChR antibody positive gMG. All claims are associated with patients who received 2 confirmed diagnoses of anti-AChR antibody positive gMG. Patients who were prescribed more than one of the biologics in this data set were counted for each biologic prescribed.

†Based on published policies from Policy Reporter as of August 2024.

AChR=acetylcholine receptor; gMG=generalized myasthenia gravis; IV=intravenous; LAAD=Longitudinal Access and Adjudication Data;

## SELECT IMPORTANT SAFETY INFORMATION

Before taking VYVGART or VYVGART HYTRULO, tell your doctor if you: take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines; have received or are scheduled to receive a vaccine (immunization); or have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

Please see Important Safety Information throughout. Please see the full Prescribing Information for [VYVGART for IV infusion](#) and [VYVGART HYTRULO for subcutaneous injection](#).

# Make the most of a treatment plan that's designed for you

**VYVGART is given in treatment cycles with a personalized break between each cycle**

Each treatment cycle is 4 treatments, 1 given each week.



You'll work with your doctor to personalize your breaks between cycles based on your symptoms and side effects.



When your symptoms start to return, talk to your doctor to help them decide when you need another cycle.

The safety of starting the next treatment cycle sooner than 4 weeks from the last treatment of the previous treatment cycle has not been established. If you miss a scheduled treatment, VYVGART may be given up to 3 days after the scheduled treatment day.

## SELECT IMPORTANT SAFETY INFORMATION

Before taking VYVGART or VYVGART HYTRULO, tell your doctor if you: take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines; have received or are scheduled to receive a vaccine (immunization); or have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

**Please see Important Safety Information throughout. Please see the full Prescribing Information for VYVGART for IV infusion and VYVGART HYTRULO for subcutaneous injection.**



# Personalized breaks may help you get the most out of your treatment plan



Learn more about treatment cycles and personalized breaks at [VYVGARTDosing.com](https://VYVGARTDosing.com).

## Tracking your symptoms consistently is important

Starting your next treatment cycle is based on your doctor's evaluation of your symptoms and any side effects you may experience. Use the MG-ADL scale to help track your symptoms.

Prezina, Kevin, and Doug are paid spokespeople of argenx.  
MG-ADL=Myasthenia Gravis Activities of Daily Living

➔ Start tracking with the interactive MG-ADL tool at [VYVGARTSymptomTracker.com](https://VYVGARTSymptomTracker.com)

## SELECT IMPORTANT SAFETY INFORMATION

Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART and VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Please see Important Safety Information throughout. Please see the full Prescribing Information for [VYVGART for IV infusion](#) and [VYVGART HYTRULO for subcutaneous injection](#).


# My VYVGART® Path

## Personalized support throughout your journey

### A Nurse Case Manager is here for you

It may feel overwhelming getting started on a new treatment. With My VYVGART Path, you'll have access to resources and one-on-one support.


My VYVGART Path is a Patient Support Program that pairs you with a dedicated Nurse Case Manager (NCM), who can help you navigate insurance, offer resources, talk through your challenges, and more.



Information provided by the Nurse Case Managers is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified and licensed physician or other healthcare provider regarding your medical condition, treatment, and healthcare needs.

NCM=Nurse Case Manager

# What you can expect from your NCM




## A personalized understanding of your treatment

My VYVGART Path NCMs are knowledgeable about VYVGART and are dedicated to listening to you and answering any questions you may have.



## Empowering resources and information

NCMs can support you throughout your treatment journey to help you in following your doctor's treatment plan.



## Hands-on help navigating the insurance process

Dealing with insurance can be complicated. An NCM can help answer any questions you have, help you understand the process, and verify what is covered by your insurance.



## Helpful information about a co-pay program and financial assistance programs

If you have financial concerns or gaps in insurance coverage for your VYVGART therapy, an NCM is here for you with information and support.

NCM=Nurse Case Manager

Already taking VYVGART?  
A Nurse Case Manager is ready to help you.

Give them a call at:  
**1-833-MY-PATH-1 (1-833-697-2841)**

Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART and VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

### **VYVGART and VYVGART HYTRULO may cause serious side effects, including:**

- **Infection.** VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
- **Allergic Reactions (hypersensitivity reactions).** VYVGART and VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.

- **Infusion-Related Reactions.** VYVGART and VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART or VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

### **Before taking VYVGART or VYVGART HYTRULO, tell your doctor if you:**

- take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
- have received or are scheduled to receive a vaccine (immunization), or
- have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

### **What are the common side effects of VYVGART and VYVGART HYTRULO?**

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common

*(Continued on page 18.)*

## IMPORTANT SAFETY INFORMATION

**VYVGART® Hytrulo**  
(efgartigimod alfa and hyaluronidase-qvfc)  
Subcutaneous Injection  
180 mg/mL and 2000 U/mL vial

**VYVGART®**  
(efgartigimod alfa-fcab)  
Injection for Intravenous Use  
400 mg/20 mL vial

*(Continued from page 17.)*

side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART and VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

**What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?**

VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

**Please see the full Prescribing Information for VYVGART and the full Prescribing Information for VYVGART HYTRULO, and talk to your doctor.**





**VYVGART® Hytrulo**  
(efgartigimod alfa and hyaluronidase-qvfc)  
Subcutaneous Injection  
180 mg/mL and 2000 U/mL vial

**VYVGART®**  
(efgartigimod alfa-fcab)  
Injection for Intravenous Use  
400 mg/20 mL vial

## VYVGART may help you do more with your day

**VYVGART helps reduce harmful AChR antibodies, the main cause of gMG symptoms.**

- ✓ When added to current oral gMG treatment, VYVGART can improve daily abilities and reduce muscle weakness in adult patients with anti-AChR antibody positive gMG\*†
- ✓ VYVGART was safe in treating most patients studied
- ✓ VYVGART offers a treatment plan based on your symptoms and side effects

\*"Improved daily abilities" was defined as a decrease of 2 or more points on the MG-ADL scale. The improvement had to be maintained for 4 or more weeks, with the first improvement occurring within 1 week of the last infusion of treatment cycle 1. The MG-ADL scale measures the severity of 8 common symptoms of gMG. A lower score means less severe symptoms.

†"Reduced muscle weakness" was defined as a decrease of 3 or more points on the QMG scale. The improvement had to be maintained for 4 or more weeks, with the first improvement occurring within 1 week of the last infusion of treatment cycle 1. The QMG scale assesses muscle weakness in gMG based on 13 items. A lower score means less muscle weakness.

AChR=acetylcholine receptor; gMG=generalized myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living; QMG=Quantitative Myasthenia Gravis  
Visit [VYVGART.com/glossary](https://www.vyvgart.com/glossary) for a glossary of terms.

**Ask your doctor  
if VYVGART is  
right for you**



**Download the  
doctor discussion  
guide and start the  
conversation with  
your doctor about  
VYVGART and your  
gMG symptoms**



### **SELECT IMPORTANT SAFETY INFORMATION**

VYVGART and VYVGART HYTRULO may cause serious side effects, including allergic reactions (hypersensitivity reactions). VYVGART and VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.

**Please see Important Safety Information throughout. Please see the full Prescribing Information for [VYVGART for IV infusion](#) and [VYVGART HYTRULO for subcutaneous injection](#).**

VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.  
For U.S. audiences only. ©2024 argenx US-ESC-22-00011 V3 11/2024

